Saint Francis, United States
Octant Ltd specializes in next-generation small molecule therapeutics targeting complex cellular mechanisms that drive disease, particularly focusing on correcting diseases of protein misfolding and mistrafficking. The company's pipeline includes projects such as OCT-980 for treating RHO-associated adRP and various undisclosed neurodegenerative and oncological conditions. OCT-980 is currently in Phase 1 clinical trials, with the Phase 1a study initiated in Q1 2026. More information about this study can be found on ClinicalTrials.gov (NCT07408232). Octant aims to redefine precision medicine by targeting root causes of genetic diseases and bringing transformative therapies from discovery to the clinic. The company is composed of technologists and builders passionate about next-generation drug discovery, combining new technologies to address complex problems.
Browsing, company names, locations and sectors are always free. A free account adds 5 contact releases every month — e-mail and phone, view or export. Need more? Contact packs start at 19 € for 50, or upgrade to a monthly plan.
Yes — no card required. Browsing is always free, and a free account adds 5 contact releases every month.
Your first 5 contact releases each month are included in the free account. After that, packs start at 19 € for 50 contacts (view or export), or a monthly plan for regular use.
Companies are harvested from the open web — registers, websites and industry directories — not self-registered sign-ups. Contact details are shown only once you use a release or credit, never invented.